In this issue:
SWIFT-1 & -2: depemokimab for severe asthma in eosinophilic phenotypes
Real-world efficacy of anti-IL-5/5Rα biologics in severe asthma
VESTIGE: dupilumab in type 2 asthma
EUFOREA consensus statement: recommendations for asthma management
Guideline-recommended asthma interventions & paediatric exacerbations
NZ Māori asthma hospitalisations 2019–23
Asthma endotypes & COVID-19
AEs with inhaled corticosteroids
Incidence of asthma with ambient air pollution
A machine learning model to predict risk of asthma attacks
Please login below to download this issue (PDF)